EW · 10-Q · 2026Q3 · Full report
Intangible Asset Impairment
Edwards Lifesciences Corp · 2026-11-04 · Importance 77 · Surprise 82 · Matches filing data
Edwards recorded $220.2 million of intangible and long-lived asset impairment charges in the three and nine months ended September 30, 2026. The charges primarily reflected the full impairment of an in-process research and development asset. The comparable 2025 periods included a $40.0 million impairment charge for a developed technology asset.
Key facts
- Edwards Lifesciences recognized intangible and long-lived asset impairment charges of $220.2 million in the three and nine months ended September 30, 2026, primarily from full impairment of an in-process research and development asset. source
- Edwards Lifesciences recognized an intangible asset impairment charge of $40.0 million in the three and nine months ended September 30, 2025, related to the full impairment of a developed technology asset. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | negative | realized | -12.8% | Edwards Lifesciences recognized intangible and long-lived asset impairment charges of $220.2 million in the three and nine months ended… |
| net_income | negative | realized | -12.8% | Edwards Lifesciences recognized intangible and long-lived asset impairment charges of $220.2 million in the three and nine months ended… |